ClinicalTrials.Veeva

Menu

Evaluation of Safety and Efficacy of a Digital Therapeutic Device to Improve Strength in Sarcopenia (Sarc-DTx)

E

Exosystems

Status

Active, not recruiting

Conditions

Sarcopenia

Treatments

Device: exoDTx
Behavioral: Self-exercise (Educational Material)

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT07319377
HC25DDDS0072

Details and patient eligibility

About

This clinical trial aims to demonstrate that the use of a digital therapeutic device (exoDTx) in patients with sarcopenia is superior to self-exercise in terms of muscle strength improvement and safety.

Full description

Background Sarcopenia is a condition characterized by progressive loss of skeletal muscle mass and strength, which is closely associated with functional decline, falls, and increased mortality.Conventional first-line treatment involves resistance training; however, in older adults, low adherence and practical challenges often limit its effectiveness.Recently, digital therapeutics (DTx) have emerged as promising tools by providing personalized exercise programs, automatic adjustment of intensity, and integrated recording and monitoring functions. These features are expected to overcome the limitations of selfdirected exercise.Therefore, this study seeks to validate the effectiveness and safety of DTx in improving muscle strength and physical function through a randomized controlled trial (RCT). Research Hypothesis In patients with sarcopenia, the group using digital therapeutics (DTx) will demonstrate superior outcomes in muscle strength improvement and safety compared to the self-exercise group.

Enrollment

130 estimated patients

Sex

All

Ages

50 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  • Individuals diagnosed with sarcopenia according to both the European Working Group on Sarcopenia in Older People (EWGSOP) criteria and the Asian Working Group for Sarcopenia 2019 (AWGS 2019) criteria
  • Individuals with reduced muscle strength, defined as at least one of the following:
  • Handgrip strength < 28 kg for men or < 18 kg for women
  • Five-times Sit-to-Stand Test time > 12 seconds without arm support
  • Individuals with reduced muscle mass, defined as at least one of the following:
  • Skeletal Muscle Mass Index (SMI) < 7.0 kg/m² for men or < 5.4 kg/m² for women measured by DXA
  • Skeletal Muscle Mass Index (SMI) < 7.0 kg/m² for men or < 5.7 kg/m² for women measured by BIA
  • Individuals able to independently perform sit-to-stand movements
  • Individuals with sufficient physical and cognitive capacity to participate in the exercise program
  • Individuals able and willing to provide written informed consent
  • Individuals able to operate a mobile phone independently or with assistance from a caregiver

Exclusion Criteria

  • Individuals with cognitive impairment, defined as a Mini-Mental State Examination (MMSE) score < 20, or those unable to participate due to cognitive decline
  • Individuals with an implanted cardiac pacemaker or other implanted electronic medical device
  • Individuals with uncontrolled cardiovascular disease despite appropriate medical management
  • Individuals who have undergone lower-limb surgery within the past 6 months and are unable to ambulate independently
  • Individuals with moderate-to-severe musculoskeletal pain or functional limitations that interfere with objective functional assessments
  • Individuals with severe obesity, defined as a body mass index (BMI) > 50 kg/m²
  • Individuals currently receiving active cancer treatment or experiencing severe systemic frailty
  • Individuals with hemiplegia that prevents participation in the prescribed exercise program
  • Individuals who are anticipated by the investigator to be unable to complete the study procedures or follow-up assessments
  • Individuals unable to understand or comply with study instructions provided in Korean
  • Individuals considered unsuitable for study participation at the discretion of the investigator for any other reason

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

130 participants in 2 patient groups

Experimental Device Group (Home-based DTx exercise group after training)
Experimental group
Description:
Participants perform personalized resistance exercises using a digital therapeutic device (mobile application) at home for 12 weeks, with sessions conducted at least 3 times per week, 50 minutes per session (≥150 minutes/week). The program includes exercise automatic intensity adjustment, exercise recording/analysis, and physician monitoring
Treatment:
Device: exoDTx
Control Group (Self-exercise)
Active Comparator group
Description:
No mobile application is used. Participants perform the same type of exercise using QR code-based educational materials, self-regulating their exercise time, at least 3 times per week, 50 minutes per session, for a total of 12 weeks, with frequency and duration identical to the experimental group.
Treatment:
Behavioral: Self-exercise (Educational Material)

Trial contacts and locations

2

Loading...

Central trial contact

Sangui Choi, CPO; Eun Ji Lee, AP

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems